Real-Life Results after the Administration of a Single 0.19 mg Fluocinolone Acetonide (ILUVIEN ® ) Implant in Patients with Refractory Diabetic Macular Edema
Ophthalmic Research · 2024
DOI: 10.1159/000540459 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ophthalmic Research, 2024. Verfasst von Warda Darwisch und 5 weiteren Autor:innen. Beteiligte Einrichtung: Knappschaft Eye Hospital Sulzbach, Sulzbach, Germany. Hauptthemen laut MEDLINE: Macular Edema, Fluocinolone Acetonide, Diabetic Retinopathy, Visual Acuity. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
The aim of this study was to evaluate real-life data on the functional and anatomical outcome of intravitreal fluocinolone acetonide (FAc) in patients with refractory diabetic macular edema (DME).
Methods
Retrospective study on 44 eyes with chronic DME that received intravitreal FAc implant and were previously treated with intravitreal dexamethasone, triamcinolone, or anti-vascular endothelial growth factor. We assessed best-corrected visual acuity (BCVA), central maximum thickness (CMT), and foveal thickness (FT) as measured by spectral-domain optical coherence tomography (Spectralis OCT; Heidelberg Engineering). Secondary outcomes were intraocular pressure (IOP), adverse events, time to additional treatments.
Results
The FAc implant significantly reduced the CMT (baseline 541.23 ± 155.29 µm, p < 0.001) and FT (baseline 460.34 ± 139.28 µm, p < 0.001) for up to 36 months. Despite postoperative visual improvement over time, BCVA did not significantly shift from baseline (0.55 ± 0.38 logMAR, p = 0.568). The FAc implant effect diminished after 21.34 ± 12.74 months. IOP increased in 9% of eyes (n = 4) but was well controlled under topical (n = 1) or surgical therapy (n = 3).
Conclusion
Even though patients’ visual recovery does not benefit significantly, the FAc implant addresses the important pillars of chronic DME therapy regarding reduced injection frequency and reduced DME.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Knappschaft Eye Hospital Sulzbach, Sulzbach, Germany.
- Augenpraxis Dielsdorf AG, Dielsdorf, Switzerland.
- Klaus Heimann Eye Research Institute (KHERI), Sulzbach, Germany.
- Department for Ophthalmology, University Eye Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.
Zitieren
APA
Darwisch, W., Della Volpe-Waizel, M., Roberts, P. K., Boden, K. T., Szurman, P., & Rickmann, A. (2024). Real-Life Results after the Administration of a Single 0.19 mg Fluocinolone Acetonide (ILUVIEN ® ) Implant in Patients with Refractory Diabetic Macular Edema. Ophthalmic Research. https://doi.org/10.1159/000540459
Vancouver
Darwisch W, Della Volpe-Waizel M, Roberts PK, Boden KT, Szurman P, Rickmann A. Real-Life Results after the Administration of a Single 0.19 mg Fluocinolone Acetonide (ILUVIEN ® ) Implant in Patients with Refractory Diabetic Macular Edema. Ophthalmic Research. 2024. doi:10.1159/000540459
BibTeX
@article{Darwisch2024,
author = {Darwisch, Warda and Della Volpe-Waizel, Maria and Roberts, Philipp K and Boden, Karl T and Szurman, Peter and Rickmann, Annekatrin},
title = {Real-Life Results after the Administration of a Single 0.19 mg Fluocinolone Acetonide (ILUVIEN ® ) Implant in Patients with Refractory Diabetic Macular Edema},
journal = {Ophthalmic Research},
year = {2024},
doi = {10.1159/000540459}
}
EUVIMED